Management of neuromuscular blockade in ambulatory patients

Current Opinion in Anaesthesiology

Volumn 27, Issue 6, 2014, Pages 583-588

  Schreiber, Jan Uwe ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Ambulatory surgery; Monitoring; Neuromuscular block; Reversal

Indexed keywords

CHOLINESTERASE INHIBITOR; CISATRACURIUM; DANTROLENE; MIVACURIUM; NEOSTIGMINE; NEUROMUSCULAR BLOCKING AGENT; ROCURONIUM; SUGAMMADEX; SUXAMETHONIUM;

AMBULATORY SURGERY; ANESTHESIOLOGICAL PROCEDURE; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DRUG CHOICE; EXTUBATION; GERIATRIC PATIENT; GYNECOLOGIC SURGERY; HUMAN; INTUBATION; LAPAROSCOPIC SURGERY; LOW DRUG DOSE; MUSCLE WEAKNESS; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR MONITORING; OUTPATIENT; PATIENT SAFETY; PEDIATRIC ANESTHESIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; RISK; SURGICAL PATIENT; ANTAGONISTS AND INHIBITORS; POSTOPERATIVE COMPLICATIONS; PROCEDURES;

AMBULATORY SURGICAL PROCEDURES; CHOLINESTERASE INHIBITORS; HUMANS; NEOSTIGMINE; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR BLOCKING AGENTS; POSTOPERATIVE COMPLICATIONS;

EID: 84927959889     PISSN: 09527907     EISSN: 14736500     Source Type: Journal    
DOI: 10.1097/ACO.0000000000000134     Document Type: Review

References (47)

1. Cutter TW. What is the role of neuromuscular blocking drugs in ambulatory anesthesia? Curr Opin Anaesthesiol 2002; 15:635-639.
2. Stomberg MW, Brattwall M, Jakobsson JG. Day surgery, variations in routines and practices a questionnaire survey. Int J Surg 2013; 11:178-182.
3. Mencke T, Echternach M, Kleinschmidt S, et al. Laryngeal morbidity and quality of tracheal intubation: a randomized controlled trial. Anesthesiology 2003; 98:1049-1056.
4. Lundstrom LH, Moller AM, Rosenstock C, et al., The Danish Anaesthesia Database. Avoidance of neuromuscular blocking agents may increase the risk of difficult tracheal intubation: a cohort study of 103 812 consecutive adult patients recorded in the Danish Anaesthesia Database. Br J Anaesth 2009; 103:283-290.
5. Combes X, Andriamifidy L, Dufresne E, et al. Comparison of two induction regimens using or not using muscle relaxant: impact on postoperative upper airway discomfort. Br J Anaesth 2007; 99:276-281.
6. Schreiber JU, Mencke T, Pradarutti S, et al. Does preoperatively administered parecoxib prevent succinylcholine-associated myalgia? A randomized, placebo-controlled trial. Eur J Anaesthesiol 2006; 23:332-337.
7. Tang J, Joshi GP, White PF. Comparison of rocuronium and mivacurium to succinylcholine during outpatient laparoscopic surgery. Anesth Analg 1996; 82:994-998.
8. Dieck T, Steffens J, Sander B, et al. Propofol, remifentanil and mivacurium: fast track surgery with poor intubating conditions. Minerva Anestesiol 2011; 77:585-591.
9. Bartolek D, Jakobovic J, Bartolek F, et al. Reduced-dose rocuronium for day-case tonsillectomy in children where volatile anaesthetics are not used: operating room time saving. Paediatr Anaesth 2010; 20:47-55.
10. Pendeville PE, Lois F, Scholtes JL. A comparison of intubation conditions and time-course of action with rocuronium and mivacurium for day case anaesthesia. Eur J Anaesthesiol 2007; 24:546-550.
11. Schlaich N, Mertzlufft F, Soltész S, Fuchs-Buder T. Remifentanil and propofol without muscle relaxants or with different doses of rocuronium for tracheal intubation in outpatient anaesthesia. Acta Anaesthesiol Scand 2000; 44:720-726.
12. Arain SR, Kern S, Ficke DJ, Ebert TJ. Variability of duration of action of neuromuscular-blocking drugs in elderly patients. Acta Anaesthesiol Scand 2005; 49:312-315.
13. Kocabas S, Yedicocuklu D, Askar FZ. The neuromuscular effects of 0.6mg kg(-1) rocuronium in elderly and young adults with or without renal failure. Eur J Anaesthesiol 2008; 25:940-946.
14. Meyhoff CS, Lund J, Jenstrup MT, et al. Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? Anesth Analg 2009; 109:787-792.
15. Leykin Y, Pellis T, Lucca M, et al. The effects of cisatracurium on morbidly obese women. Anesth Analg 2004; 99:1090-1094.
16. Martini CH, Boon M, Bevers RF, et al. Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. Br J Anaesth 2014; 112:498-505.
17. Dubois PE, Putz L, Jamart J, et al. Deep neuromuscular block improves surgical conditions during laparoscopic hysterectomy: a randomised controlled trial. Eur J Anaesthesiol 2014; 31:430-436.
18. Fuchs-Buder T, Schreiber JU, Meistelman C. Monitoring neuromuscular block: an update. Anaesthesia 2009; 64:82-89.
19. Furuya T, Suzuki T, Kashiwai A, et al. The effects of age on maintenance of intense neuromuscular block with rocuronium. Acta Anaesthesiol Scand 2012; 56:236-239.
20. Sauer M, Stahn A, Soltesz S, et al. The influence of residual neuromuscular block on the incidence of critical respiratory events. A randomised, prospective, placebo-controlled trial. Eur J Anaesthesiol 2011; 28:842-848.
21. Murphy GS, Szokol JW, Avram MJ, et al. Postoperative residual neuromus-cular blockade is associated with impaired clinical recovery. Anesth Analg 2013; 117:133-141.
22. Butterly A, Bittner EA, George E, et al. Postoperative residual curarization from intermediate-acting neuromuscular blocking agents delays recovery room discharge. Br J Anaesth 2010; 105:304-309.
23. Cammu G, De Witte J, De Veylder J, et al. Postoperative residual paralysis in outpatients versus inpatients. Anesth Analg 2006; 102:426-429.
24. White PF, Eng M. Fast-track anesthetic techniques for ambulatory surgery. Curr Opin Anaesthesiol 2007; 20:545-557.
25. Grosse-Sundrup M, Henneman JP, Sandberg WS, et al. Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study. BMJ 2012; 345:e6329.
26. Claudius C, Viby-Mogensen J. Acceleromyography for use in scientific and clinical practice: a systematic review of the evidence. Anesthesiology 2008; 108:1117-1140.
27. Murphy GS, Szokol JW, Marymont JH, et al. Intraoperative acceleromyo-graphic monitoring reduces the risk of residual neuromuscular blockade and adverse respiratory events in the postanesthesia care unit. Anesthesiology 2008; 109:389-398.
28. Murphy GS, Szokol JW, Avram MJ, et al. Intraoperative acceleromyography monitoring reduces symptoms of muscle weakness and improves quality of recovery in the early postoperative period. Anesthesiology 2011; 115:946-954.
29. Heier T, Feiner JR, Wright PM, et al. Sex-related differences in the relationship between acceleromyographic adductor pollicis train-of-four ratio and clinical manifestations of residual neuromuscular block: a study in healthy volunteers during near steady-state infusion of mivacurium. Br J Anaesth 2012; 108:444-451.
30. Samet A, Capron F, Alla F, Fuchs-Buder T. Single acceleromyographic train-of-four, 100-Hertz tetanus or double-burst stimulation: which test performs better to detect residual paralysis? Anesthesiology 2005; 102:51-56.
31. Schreiber JU, Mucha E, Fuchs-Buder T. Acceleromyography to assess neuromuscular recovery: is calibration before measurement mandatory? Acta Anaesthesiol Scand 2011; 55:328-331.
32. Liang SS, Stewart PA, Phillips S. An ipsilateral comparison of acceleromyo-graphy and electromyography during recovery from nondepolarizing neuro-muscular block under general anesthesia in humans. Anesth Analg 2013; 117:373-379.
33. Fuchs-Buder T, Baumann C, De Guis J, et al. Low-dose neostigmine to antagonise shallow atracurium neuromuscular block during inhalational anaesthesia: a randomised controlled trial. Eur J Anaesthesiol 2013; 30:594-598.
34. Fuchs-Buder T, Meistelman C, Alla F, et al. Antagonism of low degrees of atracurium-induced neuromuscular blockade: dose-effect relationship for neostigmine. Anesthesiology 2010; 112:34-40.
35. McCourt KC, Mirakhur RK, Kerr CM. Dosage of neostigmine for reversal of rocuronium block from two levels of spontaneous recovery. Anaesthesia 1999; 54:651-655.
36. Kirkegaard H, Heier T, Caldwell JE. Efficacy of tactile-guided reversal from cisatracurium-induced neuromuscularblock. Anesthesiology 2002; 96:45-50.
37. Donati F. Residual paralysis: a real problem or did we invent a new disease? Can J Anaesth 2013; 60:714-729.
38. Plaud B, Debaene B, Donati F, Marty J. Residual paralysis after emergence from anesthesia. Anesthesiology 2010; 112:1013-1022.
39. Eikermann M, Fassbender P, Malhotra A, et al. Unwarranted administration of acetylcholinesterase inhibitors can impair genioglossus and diaphragm muscle function. Anesthesiology 2007; 107:621-629.
40. Herbstreit F, Zigrahn D, Ochterbeck C, et al. Neostigmine/glycopyrrolate administered after recovery from neuromuscular block increases upper airway collapsibility by decreasing genioglossus muscle activity in response to negative pharyngeal pressure. Anesthesiology 2010; 113:1280-1288.
41. Rex C, Bergner UA, Puhringer FK. Sugammadex: a selective relaxant-binding agent providing rapid reversal. Curr Opin Anaesthesiol 2010; 23:461-465.
42. Schaller SJ, Fink H, Ulm K, Blobner M. Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block. Anesthe-siology 2010; 113:1054-1060.
43. Kotake Y, Ochiai R, Suzuki T, et al. Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block. Anesth Analg 2013; 117:345-351.
44. Blobner M, Eriksson LI, Scholz J, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. Eur J Anaesthesiol 2010; 27:874-881.
45. Geldner G, Niskanen M, Laurila P, et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuro-muscular blockade in patients undergoing laparoscopic surgery. Anaesthesia 2012; 67:991-998.
46. Ledowski T, Falke L, Johnston F, et al. Retrospective investigation of postoperative outcome after reversal of residual neuromuscular blockade: sugammadex, neostigmine or no reversal. Eur J Anaesthesiol 2014; 31:423-429.
47. Ledowski T, Hillyard S, Kozman A, et al. Unrestricted access to sugam-madex: impact on neuromuscular blocking agent choice, reversal practice and associated healthcare costs. Anaesth Intensive Care 2012; 40:340-343.